Izuralimab

艾珠利单抗

Report date: 2024/09/21 20:00:09

Base Information

Drug NameIzuralimab

Drug Alias NameXmAb-23104XmAb-104

ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Multispecific monoclonal antibody > Bispecific monoclonal antibody

Mechanisms of ActionInducible T-cell costimulator agonistsProgrammed cell death protein 1 blockers

TargetsInducible T-cell costimulatorProgrammed cell death protein 1

Therapy Area/IndicationsGastroesophageal Junction NeoplasmsSolid tumoursUterine Cervical Neoplasms +[17]

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryUnited States

CombinationsNo

Global Highest StatusPhase 1 Clinical

Highest Status in ChinaN/A

Originator CompaniesXencor Inc

China Registration ClassN/A

Develop Information

Active CompaniesXencor Inc

Inactive CompaniesN/A

Active IndicationsGastroesophageal Junction NeoplasmsSolid tumoursUterine Cervical Neoplasms +[16]

Inactive IndicationsSarcoma

Other Information

ATC CodeN/A